BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ZL-1503 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ZL-1503\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07658482-1520@assetmemo.bio
DTSTAMP:20261121T005710Z
DTSTART;VALUE=DATE:20270206
DTEND;VALUE=DATE:20270207
SUMMARY:ZL-1503: Phase 1 readout est. (NCT07658482)
DESCRIPTION:ZL-1503\, phase 1.\nStudy: A Phase 1 Study to Evaluate Pharmaco
 kinetics\, Safety and Tolerability of ZL-1503 in Healthy Volunteers\nEstim
 ated primary completion: 6 February 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/zl-1503#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07658482
URL:https://assetmemo.bio/drug/zl-1503#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07235384-1520@assetmemo.bio
DTSTAMP:20261121T005710Z
DTSTART;VALUE=DATE:20271228
DTEND;VALUE=DATE:20271229
SUMMARY:ZL-1503: Phase 1 readout est. (NCT07235384)
DESCRIPTION:ZL-1503\, phase 1\, Atopic Dermatitis.\nStudy: A Phase 1/1b Stu
 dy to Evaluate Safety\, Tolerability and Pharmacokinetics of ZL-1503 in He
 althy Volunteers and Participants With Moderate to Severe Atopic Dermatiti
 s\nEstimated primary completion: 28 December 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/zl-1503#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07235384
URL:https://assetmemo.bio/drug/zl-1503#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
